Effect of Anti-Norepinephrine Antibodies on the Development of Neuropathic Pain
- Authors: Igon’kina S.I.1, Vetrile L.A.1, Kukushkin M.L.1,2
- 
							Affiliations: 
							- Research Institute of General Pathology and Pathophysiology
- I. M. Sechenov First Moscow State Medical University
 
- Issue: Vol 162, No 6 (2017)
- Pages: 714-717
- Section: General Pathology and Pathophysiology
- URL: https://journals.rcsi.science/0007-4888/article/view/238496
- DOI: https://doi.org/10.1007/s10517-017-3695-0
- ID: 238496
Cite item
Abstract
The study focuses on induction of autoantibodies directed against neurotransmitter norepinephrine during neuropathic pain syndrome and on the effect of immunization with norepinephrine-protein conjugated antigen on the development of this syndrome. The formation of anti-norepinephrine antibodies aggravated and prolonged neuropathic pain.
About the authors
S. I. Igon’kina
Research Institute of General Pathology and Pathophysiology
														Email: mkuk57@gmail.com
				                					                																			                												                	Russian Federation, 							Moscow						
L. A. Vetrile
Research Institute of General Pathology and Pathophysiology
														Email: mkuk57@gmail.com
				                					                																			                												                	Russian Federation, 							Moscow						
M. L. Kukushkin
Research Institute of General Pathology and Pathophysiology; I. M. Sechenov First Moscow State Medical University
							Author for correspondence.
							Email: mkuk57@gmail.com
				                					                																			                												                	Russian Federation, 							Moscow; Moscow						
Supplementary files
 
				
			 
					 
						 
						 
						 
						 
				 
  
  
  
  
  Email this article
			Email this article  Open Access
		                                Open Access Access granted
						Access granted Subscription Access
		                                		                                        Subscription Access
		                                					